The epidemic of type 2 diabetes mellitus (T2DM) has afflicted more than in 1 in 10 Canadian. T2DM is associated with an increased risk of heart attacks, heart failure, stroke, blindness, kidney failure, and lower-limb amputation. Furthermore, the burden of T2DM to the healthcare system will exceed $15.36 billion over the next 10 years. Many people who have T2DM are never diagnosed until the development of a major health problem such as a heart attack or stroke. Among people with T2DM with cardiovascular risk factors, evidence-based therapies that can prevent future cardiovascular diseases from occurring. Unfortunately, it takes over a decade before evidence-based therapies are widely utilized by healthcare professionals. As a result, Canadians with T2DM are not being effectively diagnosed or treated. Artificial intelligence (A.I) represents an opportunity to address these major public health issues. The “Delivering Evidence based Care using artificial Intelligence to Patients with Diabetes and CardioVascular comorbidities” (DECIDE-CV) Innovation Project is a collaboration between McGill University Health Centre (academia), HOP Tech and Boehringer-Ingelheim (industry), The DECIDE-CV project will leverage A.I. strategies by developing deep neural network to screen electrocardiograms to identify patients at high risk of T2DM and integrate these algorithms into an electronic health care system. The development of strategies that can address these two major unmet needs in Canada can not only benefit the people with T2DM and the healthcare system, but also provides an opportunity for economic growth. The DECIDE-CV project will be one of the first to projects to develop such a multi-stakeholder collaborative partnership to improve health of people with T2DM while building the capacity for economic development in Canada.